Oncolytics Biotech Inc T.ONC

ONCY's net operating loss carryforward a/o March 31, 2022

[Noteable]

Currently equals to a minimum US$5.52 per share to any acquiring Big Pharma company.

[Noteable]

Accumulated net operating losses (NOLs) can serve as one of the keystones to a successful M&A deal. ONCY's NOLs are currently worth a minimum of US $5.51 per share to any acquiring Big Pharma company.

[Noteable]

Alternatively, a new approach to financing could become available to pre-revenue biotech companies if Congress signs off on a plan to give small biotech companies the ability to sell their net operating losses (NOLs) on the open market without actually going through the M&A process.  This plan would allow early-stage companies with an entirely new source of capital, without having